Therefore, combination blocking HLA-G with other immune checkpoints (PD-1/PD-L1 or CTLA-4) represents an inspiring strategy for cancer treatment, which may help overcome the resistance routinely developing in patients treated with a single immunotherapy. The gene discussed is HLA-G; the disease is cancer.